Aisling Capital Management LP — 13F Holdings & Portfolio
CIK 1766721 · latest 13F-HR filed 2026-11-12
Aisling Capital Management LP manages $299.3M in 13F-reported U.S. long-equity assets across 14 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are BBIO (67.92%), SNDX (8.27%), CMPS (7.20%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 0 new positions and exited 0; 3 existing positions rose in reported value and 9 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-11-12
vs 2026-06-30
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q3 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q2 26 → Q3 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 98.5%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 27, 2026.
10TH FLOOR
NEW YORK, NY 10017
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| AISLING CAPITAL PARTNERS IV LLC Control | GENERAL PARTNER since Aug 2015 | Less than 5% | Domestic Entity |
| ELMS, STEVEN, ARNOTE Control | CO-PRESIDENT since Aug 2015 | 50–75% | Individual |
| SCHIFF, ANDREW, NEWMAN Control | CO-PRESIDENT since Aug 2015 | 50–75% | Individual |
| WENZEL, ROBERT, JOHN Control | CHIEF COMPLIANCE OFFICER / CHIEF FINANCIAL OFFICER since Apr 2017 | Less than 5% | Individual |
| ELMS, STEVEN, ARNOTE Control Indirect owner via AISLING CAPITAL PARTNERS IV LLC | MEMBER since Aug 2015 | 50–75% | Individual |
| SCHIFF, ANDREW, NEWMAN Control Indirect owner via AISLING CAPITAL PARTNERS IV LLC | MEMBER since Aug 2015 | 50–75% | Individual |
Ownership & leadership changes · 5 filings with changes since Aug 31, 2015
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedWENZEL, ROBERT, JOHN · title CHIEF COMPLIANCE OFFICER / CONTROLLER → CHIEF COMPLIANCE OFFICER / CHIEF FINANCIAL OFFICER
- No longer listedAPPEL, LLOYD, ERIC · CHIEF FINANCIAL OFFICER / TREASURER / CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Aug 2015
- ChangedWENZEL, ROBERT, JOHN · title OFFICER / CONTROLLER → CHIEF COMPLIANCE OFFICER / CONTROLLER
- ChangedWENZEL, ROBERT, JOHN · title SECRETARY / CONTROLLER → OFFICER / CONTROLLER
- ChangedELMS, STEVEN, ARNOTE · indirect via AISLING CAPITAL PARTNERS IV LLC: title CO-OWNER → MEMBER
- ChangedSCHIFF, ANDREW, NEWMAN · indirect via AISLING CAPITAL PARTNERS IV LLC: title CO-OWNER → MEMBER
- AddedELMS, STEVEN, ARNOTE · CO-OWNER · 50–75% · indirect via AISLING CAPITAL PARTNERS IV LLC · control person
- AddedSCHIFF, ANDREW, NEWMAN · CO-OWNER · 50–75% · indirect via AISLING CAPITAL PARTNERS IV LLC · control person
- ListedAISLING CAPITAL PARTNERS IV LLC · GENERAL PARTNER · Less than 5% · control person
- ListedAPPEL, LLOYD, ERIC · CHIEF FINANCIAL OFFICER / TREASURER / CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ListedELMS, STEVEN, ARNOTE · CO-PRESIDENT · 50–75% · control person
- ListedSCHIFF, ANDREW, NEWMAN · CO-PRESIDENT · 50–75% · control person
- ListedWENZEL, ROBERT, JOHN · SECRETARY / CONTROLLER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- COMPASS PATHWAYS PLC$1.3M +6.3%
- EUPRAXIA PHARMACEUTICALS INC$809.2K +37.7%
- UROGEN PHARMA LTD$413.6K +10.4%
Top Trims
- BRIDGEBIO PHARMA INC-$138.5M -40.5%
- MONTE ROSA THERAPEUTICS INC-$19.1M -50.7%
- BICARA THERAPEUTICS INC-$6.7M -39.5%
- SYNDAX PHARMACEUTICALS INC-$4.0M -14.0%
- BRIDGEBIO ONCOLOGY THERAPEUT-$3.6M -46.7%
Aisling Capital Management LP Holdings (2026-09-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $203.3M | 67.92% | 3,089,611 | SH |
| 2 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $24.8M | 8.27% | 1,316,806 | SH |
| 3 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $21.6M | 7.20% | 1,732,336 | SH |
| 4 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $18.6M | 6.20% | 1,555,664 | SH |
| 5 | BICARA THERAPEUTICS INC | BCAX | 055477103 | $10.2M | 3.41% | 548,919 | SH |
| 6 | UROGEN PHARMA LTD | URGN | M96088105 | $4.4M | 1.47% | 108,000 | SH |
| 7 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 107924102 | $4.1M | 1.38% | 1,018,018 | SH |
| 8 | EUPRAXIA PHARMACEUTICALS INC | EPRX | 29842P105 | $3.0M | 0.99% | 325,000 | SH |
| 9 | BIOMEA FUSION INC | BMEA | 09077A106 | $2.7M | 0.92% | 2,048,757 | SH |
| 10 | ACLARIS THERAPEUTICS INC | ACRS | 00461U105 | $2.3M | 0.76% | 434,455 | SH |
| 11 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $2.0M | 0.68% | 42,031 | SH |
| 12 | VTV THERAPEUTICS INC | VTVT | 918385204 | $1.8M | 0.61% | 58,775 | SH |
| 13 | MARKER THERAPEUTICS INC | MRKR | 57055L206 | $348.1K | 0.12% | 325,370 | SH |
| 14 | ONKURE THERAPEUTICS INC | OKUR | 68277Q105 | $241.5K | 0.08% | 88,607 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-12 | $299.3M | 14 | 0001766721-26-000004 |
| 2026-06-30 | 2026-08-13 | $471.6M | 14 | 0001766721-26-000003 |
| 2026-03-31 | 2026-05-05 | $476.3M | 13 | 0001766721-26-000002 |
| 2025-12-31 | 2026-02-10 | $478.9M | 13 | 0001766721-26-000001 |
NEW YORK, NY 10017